Alphatec (ATEC) vs AtriCure (ATRC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
AtriCure (ATRC) has outperformed Alphatec (ATEC) over the past year, gaining 50.6% versus a loss of 26.2%. Over five years, ATEC leads with a -15.1% price change compared with -26.0% for ATRC. AtriCure is the larger company by market cap ($2.69 billion vs $1.60 billion), about 1.7 times the size, while Alphatec is growing revenue faster (+25.0% vs +14.9%).
On valuation, Alphatec trades at a lower forward P/E (17.2x vs 121.8x for AtriCure). AtriCure converts more of its revenue into profit, with a net margin of -2.1% versus -18.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATEC | ATRC |
|---|---|---|
| Share price | $10.35 | $52.84 |
| Market cap | $1.60B | $2.69B |
| 1-day change | +0.98% | -0.88% |
| YTD return | -50.81% | +33.57% |
| 1-year return | -26.18% | +50.63% |
| 5-year return | -15.09% | -25.96% |
| P/E ratio (TTM) | — | 251.62 |
| Forward P/E | 17.24 | 121.76 |
| EPS (TTM) | $-0.72 | $0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $764.15M | $534.53M |
| Revenue growth (YoY) | +24.95% | +14.88% |
| Net income (latest FY) | $-143.36M | $-11.45M |
| Gross margin | 69.60% | 74.98% |
| Operating margin | -10.75% | -1.77% |
| Net margin | -18.76% | -2.14% |
| 52-week high | $23.29 | $61.70 |
| 52-week low | $6.82 | $25.36 |
| Distance from 52-week high | -55.56% | -14.36% |
| Analyst consensus | none | buy |
| Avg. price target upside | +52.56% | +3.88% |
| Average volume | 2.14M | 1.08M |
| Shares outstanding | 154.45M | 50.87M |
| Employees | 913 | 1,350 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATRC has outperformed ATEC by 76.8 percentage points over the past year.
- AtriCure is more profitable, keeping -2.1 cents of every revenue dollar as net income versus -18.8 cents for Alphatec.
- Alphatec grew revenue faster in its latest fiscal year (+24.95% vs +14.88%).
About Alphatec
ATEC stock →Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. The company manufactures and sells implants, instruments, imaging equipment, and spare parts.
Health Care · Medical/Dental Instruments · 913 employees
About AtriCure
ATRC stock →AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally.
Health Care · Medical/Dental Instruments · 1,350 employees
ATEC vs ATRC FAQ
Which is bigger, Alphatec or AtriCure?
AtriCure (ATRC) is larger, with a market capitalization of $2.69B compared with $1.60B for Alphatec (ATEC).
Which stock has performed better over the past year, ATEC or ATRC?
ATRC returned +50.63% over the past 12 months, compared with -26.18% for ATEC (price return, excluding dividends). Past performance does not predict future results.
Are Alphatec and AtriCure in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.